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Albany Medical College, The Institute for Vascular Health and Disease, The Vascular Group, PLLC, 43 New Scotland Avenue (MC157), Albany, NY 12208, United StatesI read this manuscript with interest as this prospective, case-
controlled pilot study represents a multi-specialty collaboration
amongst vascular surgeons, interventionists, and neurologists that
adds to our understanding of the implications of CCSVI in MS
patients. The fundamental value of a pilot study is that it can be
used to test the design for a larger-scale study and, in this case,
gives us a glimpse into the potential qualitative measures and
treatment outcomes that could be explored in MS patients with
CCSVI. Zamboni’s study evaluates 15 patients with CCSVI associated
with relapse remitting MS who underwent immediate vs. delayed
(6 months) internal jugular and/or azygous venous angioplasty.
Parameters evaluated were well beyond safety and feasibility, and
include T1- and T2-weighted MRI assessment of changes in the
number and volume of the demyelinated CNS lesions, percent brain
volume changes, as well as clinical correlations with EDSS and
MSFC. These are parameters that are well accepted by international
MS and Neurology societies.
The conclusions of this pilot study conﬁrm ﬁndings from larger-
scale reports that angioplasty of the internal jugular and azygous
veins is relatively safe. These results are encouraging and indicate
signiﬁcant improvements in MSFC scores post treatment as well as* Tel.: þ1 518 262 5640; fax: þ1 518 262 6720.
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on MRI. These ﬁndings of lesion volume reduction are of great
interest and might enable us to design trials with the ability to
evaluate other important endpoints following interventions for
CCSVI.
Another potentially important ﬁnding from this study is that
regardless of the safety of PTA, its longevity remains questionable. If
CCSVI diagnosis and treatment has merit then surgical venous
reconstructive procedures for CCSVI will have to be considered
(rather than angioplasty) in order to improve the patency and
longevity of these treatments.
This pilot study is of importance. This is not just because it
conﬁrms the safety and feasibility of PTA for CCSVI (with the
prospect of improved clinical and MRI outcomes in the short term),
but it emphasizes the beneﬁt of multidisciplinary collaboration to
conduct research and problem solving in this controversial subject.
Moreover, like any pilot study, we are now left with more questions
than answers. The evolution of diagnostic methods and treatment
for CCSVI in MS patients will have to involve a collaborative
multidisciplinary effort; something that many of us are eagerly
awaiting.d by Elsevier Ltd. All rights reserved.
